<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09617</article-id><article-id pub-id-type="doi">10.7554/eLife.09617</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-37221"><name><surname>Hermann</surname><given-names>Clemens</given-names></name><aff><institution content-type="dept">Department of Integrated Biomedical Sciences, Division of Chemical and 20 Systems Biology, Institute for Infectious Disease and Molecular Medicine</institution>, <institution>University of Cape Town</institution>, <addr-line><named-content content-type="city">Cape Town</named-content></addr-line>, <country>South Africa</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-37222"><name><surname>van Hateren</surname><given-names>Andy</given-names></name><aff><institution content-type="dept">Faculty of Medicine and Institute for Life Science</institution>, <institution>University of Southampton</institution>, <addr-line><named-content content-type="city">Southampton</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-37223"><name><surname>Trautwein</surname><given-names>Nico</given-names></name><aff><institution content-type="dept">Department of Immunology</institution>, <institution>Eberhard Karls University Tübingen</institution>, <addr-line><named-content content-type="city">Tübingen</named-content></addr-line>, <country>Germany</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-37224"><name><surname>Neerincx</surname><given-names>Andreas</given-names></name><aff><institution content-type="dept">Department of Pathology</institution>, <institution>University of Cambridge</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-37225"><name><surname>Duriez</surname><given-names>Patrick J</given-names></name><aff><institution content-type="dept">Cancer Research UK Protein Core Facility, Faculty of Medicine</institution>, <institution>University of Southampton</institution>, <addr-line><named-content content-type="city">Southampton</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32347"><name><surname>Stevanović</surname><given-names>Stefan</given-names></name><aff><institution content-type="dept">Department of Immunology</institution>, <institution>Eberhard Karls University Tübingen</institution>, <addr-line><named-content content-type="city">Tübingen</named-content></addr-line>, <country>Germany</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-33933"><name><surname>Trowsdale</surname><given-names>John</given-names></name><aff><institution content-type="dept">Department of Pathology</institution>, <institution>University of Cambridge</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15515"><name><surname>Deane</surname><given-names>Janet E</given-names></name><aff><institution content-type="dept">Cambridge Institute for Medical Research</institution>, <institution>University of Cambridge</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-37226"><name><surname>Elliott</surname><given-names>Tim</given-names></name><aff><institution content-type="dept">Faculty of Medicine and Institute for Life Science</institution>, <institution>University of Southampton</institution>, <addr-line><named-content content-type="city">Southampton</named-content></addr-line>, <country>United Kingdom</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-36640"><name><surname>Boyle</surname><given-names>Louise H</given-names></name><aff><institution content-type="dept">Department of Pathology</institution>, <institution>University of Cambridge</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country><email>lhb22@cam.ac.uk</email></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1136"><name><surname>Mathis</surname><given-names>Diane</given-names></name><role>Reviewing editor</role><aff><institution>Harvard Medical School</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>06</day><month>10</month><year>2015</year></pub-date><volume>4</volume><elocation-id>e09617</elocation-id><supplementary-material><ext-link xlink:href="elife-09617-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>22</day><month>06</month><year>2015</year></date><date date-type="accepted"><day>05</day><month>10</month><year>2015</year></date></history><permissions><copyright-statement>© 2015, Hermann et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Hermann et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>Our understanding of the antigen presentation pathway has recently been enhanced with the identification that the tapasin-related protein TAPBPR is a second MHC I-specific chaperone. We sought to determine whether, like tapasin, TAPBPR can also influence MHC I peptide selection by functioning as a peptide exchange catalyst. We show that TAPBPR can catalyse the dissociation of peptides from peptide-MHC I complexes, enhance the loading of peptide-receptive MHC I molecules, and discriminate between peptides based on affinity <italic>in vitro</italic>. In cells, the depletion of TAPBPR increased the diversity of peptides presented on MHC I molecules, suggesting that TAPBPR is involved in restricting peptide presentation. Our results suggest TAPBPR binds to MHC I in a peptide-receptive state and, like tapasin, works to enhance peptide optimisation. It is now clear there are two MHC class I specific peptide editors, tapasin and TAPBPR, intimately involved in controlling peptide presentation to the immune system.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></back></article>